Securities code: 002349 securities abbreviation: Jinghua Pharmaceutical Group Co.Ltd(002349) Announcement No.: 2022-003 Jinghua Pharmaceutical Group Co.Ltd(002349)
Announcement on abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and are responsible for any false information in the announcement
Be responsible for records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Jinghua Pharmaceutical Group Co.Ltd(002349) (hereinafter referred to as “the company”) shares (securities code: 002349, securities abbreviation: Jinghua Pharmaceutical Group Co.Ltd(002349) ) have deviated from the closing price for two consecutive trading days on January 13, 2022 and January 14, 2022 by more than 20%. According to the relevant regulations of Shenzhen Stock Exchange, it belongs to the abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the board of directors of the company has verified the relevant problems, and now the relevant information is explained as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage.
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
3. The company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or major events in the planning stage.
4. During the period of stock change, the controlling shareholders of the company did not buy or sell the company’s shares.
5. The company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with relevant provisions such as the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed of the information that should be disclosed by the company according to the stock listing rules of Shenzhen Stock Exchange and other relevant provisions, which has a great impact on the stock trading price of the company; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The information disclosure media designated by the company are securities times and http://www.cn.info.com.cn, All information publicly disclosed by the company shall be published in the above designated media
Securities code: 002349 securities abbreviation: Jinghua Pharmaceutical Group Co.Ltd(002349) Announcement No.: 2022-003 announcement shall prevail.
3. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Jinghua Pharmaceutical Group Co.Ltd(002349) board of directors January 17, 2022
